Travere Therapeutics, Inc. TVTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| —— | -$321.55M-189% | -$111.4M+60.0% | -$278.48M-54.6% | ||
| $60.74M+39.5% | $43.56M+13.0% | $38.53M+79.1% | $21.51M— | ||
| $44.87M+21.6% | $36.91M-16.6% | $44.25M+16.0% | $38.14M+29.0% | ||
| —— | -$237.48M+15.2% | -$280.02M-50.3% | -$186.29M— | ||
| —— | —— | —— | -$32.55M— | ||
| —— | $139.42M-36.4% | $219.39M+86.6% | $117.57M-49.3% | ||
| —— | $359K+110% | -$3.51M+96.6% | -$104.07M-229% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Travere Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Travere Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.